Genelux Corporation (GNLX)

NCM – Real Time Price. Currency in USD

2.97

+0.07 (2.41%)

At close: May 12, 2026, 4:00 PM EDT

2.91

-0.06 (-2.02%)

After-hours: May 12, 2026, 6:52 PM EDT

07.05.2026

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026; expected to fund operations into 1Q27 -- WESTLAKE VILLAGE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates.

19.03.2026

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 --

12.01.2026

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT.

08.01.2026

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share.

07.01.2026

Genelux Corporation Announces Proposed Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

02.01.2026

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones.

05.11.2025

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --

Videos

No Data

There is no data to display

Press releases

07.05.2026

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

19.03.2026

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

12.01.2026

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

08.01.2026

Genelux Corporation (GNLX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Genelux Corporation (GNLX)

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Videos

No Data

Press releases

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Videos

No Data

Press releases

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Search stocks

Genelux Corporation (GNLX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Genelux Corporation (GNLX)

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Videos

No Data

Press releases

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Videos

No Data

Press releases

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock